First-in-Human safety check for experimental drug LY4178256

NCT ID NCT07698210

Not yet recruiting Knowledge-focused Sponsor: Eli Lilly and Company Source: ClinicalTrials.gov ↗

First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time

Summary

This early-stage trial evaluates the safety and tolerability of a new drug called LY4178256 in healthy volunteers. Participants receive either the drug or a placebo intravenously, and researchers monitor side effects and how the body processes the drug. The study lasts about 7 months and includes up to 12 visits. Results will help determine if LY4178256 is safe enough to test in people with medical conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LY4178256
What this could lead to: If safe and well-tolerated, this could pave the way for future studies of LY4178256 in people with specific diseases.
What could go wrong: This is an early phase 1 trial in only 88 healthy people, so results may not predict effects in patients. Side effects are unknown and being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS

Contacts and locations

Locations

Collaborative Neuroscience Network - CNS

Los Alamitos, California, 90720, United States
ICON

Salt Lake City, Utah, 84124, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.